Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Positive Nodes Clear all
Completed Phase 1Phase 2 Interventional Results available

A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer

NCT00581256
View directory record Official record
Conditions
Breast Cancer
Interventions
IMRT, 3D
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

NCT01076335
View directory record Official record
Conditions
Prostate Cancer
Interventions
Neoadjuvant Hormonal Therapy, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jul 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer

NCT06559540
View directory record Official record
Conditions
Node-positive Breast Cancer
Interventions
Hypofractionated radiation, Ultra-hypofractionated breast/chest wall and regional nodal radiation
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Electronic Medical Record-Based Nudge to Reduce SLNB

NCT06006910
View directory record Official record
Conditions
Breast Cancer, Estrogen-receptor-positive Breast Cancer
Interventions
Column-based nudge in the EHR, No column-based nudge in the EHR
Behavioral
Lead sponsor
University of Pittsburgh Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 22, 2026, 10:02 AM EDT
Active, not recruiting Not applicable Interventional

Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65

NCT02564848
View directory record Official record
Conditions
Breast Cancer
Interventions
Lumpectomy without sentinel node biopsy
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
65 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

NCT07076485
View directory record Official record
Conditions
Breast Cancer
Interventions
Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Loveland, Colorado • Voorhees Township, New Jersey • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Results available

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

NCT02780401
View directory record Official record
Conditions
HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes

NCT02700386
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Hypofractionated Radiation
Combination Product
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

NCT03219476
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer
Interventions
Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

NCT00012012
View directory record Official record
Conditions
Cervical Cancer, Radiation Toxicity
Interventions
Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
17
States / cities
Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Jul 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

NCT00004067
View directory record Official record
Conditions
Breast Cancer
Interventions
herceptin, adriamycin, cyclophosphamide, taxol
Biological · Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
2,130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2019
U.S. locations
141
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Early Phase 1 Interventional

SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer

NCT03411070
View directory record Official record
Conditions
Positive Axillary Lymph Node, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Implanted Medical Device, Therapeutic Conventional Surgery
Device · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Jul 22, 2026, 10:02 AM EDT
Active, not recruiting Not applicable Interventional

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

NCT03460067
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Omission of Radiation
Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Jul 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy

NCT00590967
View directory record Official record
Conditions
Cervical Cancer
Interventions
IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

NCT00544167
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Jacksonville, Florida • Orlando, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2013 · Synced Jul 22, 2026, 10:02 AM EDT
Recruiting Phase 3 Interventional

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616
View directory record Official record
Conditions
Breast Cancer
Interventions
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
170
States / cities
Daphne, Alabama • Chandler, Arizona • Gilbert, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874
View directory record Official record
Conditions
Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
895
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

NCT00119262
View directory record Official record
Conditions
Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, bevacizumab, paclitaxel, filgrastim, pegfilgrastim, radiation therapy, tamoxifen citrate, aromatase inhibition therapy
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy

NCT01901094
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1228
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jul 22, 2026, 10:02 AM EDT
Recruiting Phase 2 Interventional

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

NCT07276880
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
Interventions
Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 10:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319
View directory record Official record
Conditions
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions
DS-8201a, T-DM1
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
126
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 10:02 AM EDT